Bioresonance therapy appears to improve antioxidant defense mechanisms in patients with rheumatoid arthritis by increasing glutathione levels and normalizing key antioxidant enzyme activities. These findings suggest a potential supportive role for bioresonance therapy in reducing oxidative stress and enhancing cellular protective responses in RA patients. Further controlled clinical studies are required to confirm these effects and clarify the underlying mechanisms.
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with oxidative stress and impaired antioxidant defense mechanisms. This study evaluated the activities of major antioxidant enzymes, including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), as well as the level of nonprotein thiol groups (reduced glutathione, GSH) in blood lymphocytes of RA patients before and during
bioresonance therapy. Patients receiving conventional pharmacotherapy showed elevated antioxidant enzyme activities accompanied by reduced thiol group content, indicating persistent oxidative imbalance. Following bioresonance therapy, thiol group levels increased and the activities of SOD and GPx approached normal values, while catalase activity remained elevated compared with controls. These findings suggest that bioresonance therapy may contribute to the activation of nonspecific protective mechanisms and improvement of antioxidant status in patients with RA.
Introduction
Oxidative stress plays a significant role in the pathogenesis and progression of rheumatoid arthritis. Excessive production of reactive oxygen species can damage cellular structures and disrupt immune regulation. Antioxidant enzymes such as SOD, CAT, and GPx constitute an important defense system against oxidative injury. Reduced glutathione is another critical intracellular antioxidant involved in maintaining redox balance.
Materials and Methods
Blood lymphocytes were collected from patients diagnosed with rheumatoid arthritis before and during bioresonance therapy. Activities of SOD, CAT, and GPx were measured using standard biochemical assays. The content of nonprotein thiol groups, primarily reduced glutathione, was also determined. Patients receiving standard pharmacological treatment served as the comparison group.
Results
Patients undergoing standard pharmacotherapy demonstrated increased activities of antioxidant enzymes together with decreased glutathione levels, reflecting oxidative stress and compensatory activation of antioxidant defenses.
During
bioresonance therapy, a significant increase in thiol group content was observed. Activities of SOD and GPx gradually normalized, suggesting partial restoration of the intracellular antioxidant balance. Catalase activity, although reduced compared with pretreatment levels, remained above control values.
Discussion
The observed normalization of antioxidant parameters indicates that bioresonance therapy may positively influence cellular redox regulation in RA patients. Increased glutathione content suggests improved intracellular antioxidant capacity, while normalization of SOD and GPx activities may reflect reduced oxidative burden.
Persistent elevation of catalase activity could indicate continued adaptive protection against hydrogen peroxide accumulation. Overall, the data support the hypothesis that bioresonance therapy activates nonspecific protective and compensatory mechanisms in rheumatoid arthritis.
Conclusion
Bioresonance therapy appears to improve antioxidant defense mechanisms in patients with rheumatoid arthritis by increasing glutathione levels and normalizing key antioxidant enzyme activities. These findings suggest a potential supportive role for bioresonance therapy in reducing oxidative stress and enhancing cellular protective responses in RA patients.
